Trevi Therapeutics, Inc. Common Stock
$14.95
-$0.26 (-1.71%)
$14.81Day Range$15.38
Key Statistics
Market Cap
$2.17B
Shares Outstanding
142.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 3, 2019
Round Lot
100
Locale
US
Trading Data
Day Open
$15.17
Day High
$15.38
Day Low
$14.81
Volume
2.14M
VWAP
$14.96
Prev Close
$15.21
Transactions
--
Acc. Volume
--
About Trevi Therapeutics, Inc. Common Stock
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
PHARMACEUTICAL PREPARATIONSSIC 283434 employees195 CHURCH STREET, NEW HAVEN, CT, 06510203-304-2499IPO May 3, 2019US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001563880
- Composite FIGI
- BBG003QGQRB9
- Share Class FIGI
- BBG003QGQRC8
- Ticker Root
- TRVI
- SIC Code
- 2834
About Trevi Therapeutics, Inc. Common Stock (TRVI) Stock
Trevi Therapeutics, Inc. Common Stock (TRVI) closed the 2026-09-18 session at $14.95, down 1.71% versus the previous close (-0.26). The stock opened at $15.17 and traded between $14.81 and $15.38 during that session. Session trading volume was 2.1M shares. The volume-weighted average price (VWAP) is $14.96.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Trevi Therapeutics, Inc. Common Stock has a market capitalization of $2.17 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. TRVI is listed on the XNAS exchange. The company employs approximately 34 people. Trevi Therapeutics, Inc. Common Stock is headquartered in NEW HAVEN, CT. The recorded listing date is 2019-05-03.
On this page you can find market TRVI stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.